加载中
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
前收盘价
US$10.16
+US$1.22 · +13.65%
盘前
US$10.10
−US$0.06 · -0.59%
10月12日 7:14 ET
盘中时间采用ET。市场数据可能有所延迟。
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
日内区间
当前US$10.16
52周区间
当前US$10.16
盘中时间采用ET。市场数据可能有所延迟。
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
日内区间
当前US$10.16
52周区间
当前US$10.16
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 280万 USD | 453.4万 USD | 571.8万 USD | 574.7万 USD | 478.2万 USD |
| 销货成本 | 1174.2万 USD | 6245.9万 USD | 4756.7万 USD | 5890.8万 USD | 4458.6万 USD |
| 毛利 | −894.2万 USD | −5792.5万 USD | −4184.9万 USD | −5316.1万 USD | −3980.4万 USD |
| 研究与开发 | 8141.8万 USD | 6385.9万 USD | 4806.7万 USD | 5890.8万 USD | 4458.6万 USD |
| 销售、一般及管理费用 | 3505.8万 USD | — | — | — | — |
| 营业费用 | 1.16亿 USD | 5096.3万 USD | 7366.6万 USD | 5358.9万 USD | 3543.4万 USD |
| 利息支出 | 20.9万 USD | 56.5万 USD | 101万 USD | 97.2万 USD | 343.2万 USD |
| 折旧和摊销 | 1174.2万 USD | 1338.9万 USD | 1399.9万 USD | 1310万 USD | 665.4万 USD |
| 营业利润 | −1.25亿 USD | −1.09亿 USD | −1.16亿 USD | −1.07亿 USD | −7523.8万 USD |
| 净利润 | −1.15亿 USD | −1.03亿 USD | −1.11亿 USD | −1.05亿 USD | −1.01亿 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$13.60
上涨空间 33.86%报告持有此股票敞口的交易所交易基金。
ARK Genomic Revolution ETFARKG9459.5万4.62%15.57亿 USD0.75%US$51.30+4.08%
State Street SPDR S&P Biotech ETFXBI4481.88万0.45%98.74亿 USD0.35%US$153.77+3.00%
Vanguard Morningstar Total Stock Market ETFVTI4034.32万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM3534.87万0.05%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF1439.53万0.01%954亿 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO1035.75万0.08%139.17亿 USD0.24%US$356.78+0.94%
iShares Biotechnology ETFIBB1024.01万0.10%108.2亿 USD0.44%US$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA765.87万0.04%218.24亿 USD0.03%US$32.79+0.40%ARK Genomic Revolution ETFARKGState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
